Japan Digestive Disease Week 2025
Invited Lecture (JGES)
October 31, 9:00–9:30, Room 11 (Portopia Hotel South Wing Topaz)
Invited Lecture-8
Endoscopic management of malignant pancreatic tumor
- Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine
Introduction
Malignant pancreatic tumors are nowadays effectively managed by endoscopic retrograde cholangiopancreatography (ERCP) and endoscopic ultrasound (EUS) approaches. Among them, EUS-guided pancreatic tumor management is relatively new field and there has been marked advancement during last decade.
EUS-guided tumor ablation
EUS-guided direct tumor ablation is also tried by various methods such as EUS-guided radiofrequency ablation (EUS-RFA) or cryotherapy. EUS-RFA is actively investigated to several pancreatic tumors such as neuroendocrine tumors, solid pseudopapillary tumors and pancreatic cancers. Technical feasibility and clinical response rate seem to be higher than 90% and 80%, respectively. There can be some complications but reported complications are not frequent and severe. Therefore treatment response seems to be good based on several pilot studies.
Conclusion
EUS-guided management of malignant pancreatic tumors are making rapid progress. EUS-guided direct tumor ablation became possible. Although initial studies show relatively good response and safety, more studies are required to increase the efficacy and reduce possible complications.
Malignant pancreatic tumors are nowadays effectively managed by endoscopic retrograde cholangiopancreatography (ERCP) and endoscopic ultrasound (EUS) approaches. Among them, EUS-guided pancreatic tumor management is relatively new field and there has been marked advancement during last decade.
EUS-guided tumor ablation
EUS-guided direct tumor ablation is also tried by various methods such as EUS-guided radiofrequency ablation (EUS-RFA) or cryotherapy. EUS-RFA is actively investigated to several pancreatic tumors such as neuroendocrine tumors, solid pseudopapillary tumors and pancreatic cancers. Technical feasibility and clinical response rate seem to be higher than 90% and 80%, respectively. There can be some complications but reported complications are not frequent and severe. Therefore treatment response seems to be good based on several pilot studies.
Conclusion
EUS-guided management of malignant pancreatic tumors are making rapid progress. EUS-guided direct tumor ablation became possible. Although initial studies show relatively good response and safety, more studies are required to increase the efficacy and reduce possible complications.